Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "applications"

618 News Found

Avient introduces non-PFAS GlideTech formulations for catheters
Medical Device | January 07, 2026

Avient introduces non-PFAS GlideTech formulations for catheters

GlideTech materials are available in several standard base resins and offer customization options for specific applications


BioVarta 2025 puts the spotlight on translating biotech innovation into impact
News | January 04, 2026

BioVarta 2025 puts the spotlight on translating biotech innovation into impact

Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale


Biotium launches GlycoLiner kits for fast & selective cell surface glycoprotein labelling
News | January 03, 2026

Biotium launches GlycoLiner kits for fast & selective cell surface glycoprotein labelling

Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols


Enveric Biosciences bags key US patent for next-gen neuropsychiatric drugs
Biotech | January 01, 2026

Enveric Biosciences bags key US patent for next-gen neuropsychiatric drugs

The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”


Co-Diagnostics scores major IP win in Australia with first patent for PCR platform
News | January 01, 2026

Co-Diagnostics scores major IP win in Australia with first patent for PCR platform

The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments


GenSight Biologics gets early access nod for candidate gene therapy in Israel
Clinical Trials | December 31, 2025

GenSight Biologics gets early access nod for candidate gene therapy in Israel

Applications include detailed scientific rationale and supporting clinical evidence


CARsgen submits INDs for next-gen CAR-T therapy targeting hard-to-treat blood cancers
Clinical Trials | December 31, 2025

CARsgen submits INDs for next-gen CAR-T therapy targeting hard-to-treat blood cancers

The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively


Ipsen acquires Simcere Zaiming’s innovative ADC SIM0613
Biopharma | December 24, 2025

Ipsen acquires Simcere Zaiming’s innovative ADC SIM0613

The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.